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Notch  receptor  signaling  pathways  play  an  important  role,  not  only  in  normal  breast development  but
also in breast  cancer  development  and  progression.  As  a group  of ligand-induced  proteins,  different
subtypes  of mammalian  Notch  (Notch1-4)  are  sensitive  to  subtle  changes  in  protein  levels.  Thus,  a  clear
understanding  of  mechanisms  of Notch  protein  turnover  is essential  for understanding  normal  and  patho-
logical  mechanisms  of  Notch  functions.  It has  been  suggested  that there  is a close  relationship  between  the
carcinogenesis  and  the dysregulation  of  Notch  degradation.  However,  this  relationship  remains  mostlybiquitin-proteasome system
egradation
undeﬁned  in the  context  of  breast  cancer,  as  protein degradation  is mediated  by numerous  signaling
pathways  as  well  as  certain  molecule  modulators  (activators/inhibitors).  In this  review,  we  summarizereast cancer the  published  data  regarding  the  regulation  of  Notch  family  member  degradation  in  breast  cancer,  while
herapy emphasizing  areas  that  are  like
drugs.
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. Introduction
Breast cancer is the most common cancer diagnosed among
omen worldwide. According to recent global cancer statistics
eleased by the IARC (International Agency for Research on Can-
er), breast cancer accounts for 25% of all types of cancer cases and
5% of all cancer deaths among females (Torre et al., 2015). Current
tandardized therapy for breast cancer, used often in combination,
ncludes surgery, radiation, hormone therapy, and chemothera-
eutic agents such as anthracyclines, cyclophosphamide, taxanes
nd platinum compounds (Ono et al., 2015). However, recurrence
till occurs in a substantial proportion of breast cancer patients
fter comprehensive treatment. Besides the HER2 signaling path-
ay when over-expressed, Notch signaling has also been described
s a major player in breast cancer cells, in particular in cancer
tem cells (McCubrey et al., 2014; Ischenko et al., 2008). Aber-
ant activation and dysregulation of Notch pathways have been
etected in breast cancer (Stylianou et al., 2006). This is corrob-
rated by Notch involvement in a number of oncogenic signaling
athways and drug resistance incidents (Guo et al., 2011). How-
ver, the intricacies of Notch signaling mechanisms in breast cancer
rogression remain elusive and controversial. In this review, we
escribe some central mechanistic aspects of Notch degradation
n breast cancer. In addition, we discuss anti-cancer therapeutic
gents that selectively target Notch. Finally, we evaluate how Notch
own-regulation is likely to participate given current knowledge in
reast cancer research and highlight potential clinical implications
or Notch down-regulation in this malignant disease.
. Overview of the Notch signaling pathway
The Notch (neurogenic locus notch homologue protein) path-
ay is an evolutionarily conserved signaling pathway that
egulates stem cell maintenance, cell fate speciﬁcation, differen-
iation, proliferation, motility, and survival. Throughout the past
everal decades, the function of Notch proteins have been stud-
ed in many diverse organisms, from worms to humans, beginning
n 1919 with its discovery and naming based on its effect on the
artial loss of wings phenotype in Drosophila (Artavanis-Tsakonas,
988). Since then, numerous researchers have contributed to the
iscovery of the components and various regulators to the Notch
ignaling pathway involved in the loss of wings phenotype. Differ-
nt organisms possess different, yet homologous, Notch receptors.
or example, Drosophila have only one receptor (Notch) and two
igands (Delta and Serrate) while mammals possess more com-
licated components of the Notch signaling pathway, which is
onsistent with the more diverse array of Notch function in humans
Andersson et al., 2011). Although homologous Notch receptors
iffer in their extracellular and cytoplasmic domains, they exhibit
emarkable similarity in function.
In mammalian signal-sending cells, the Notch pathway con-
ists of ligands (Delta-like proteins 1/3/4, Jagged1/2) and receptors
Notch1/2/3/4) (Ilagan and Kopan, 2007). Notch ligands contain
n amino-terminal Notch ligand motif (in all ligands except for
he Notch inhibitory ligand DLL3), followed by an N-terminal DSL
Delta-Serrate-LAG-2) domain, specialized tandem EGF repeats
called a DOS domain, Delta and OSM-11) and EGF-like repeats.
he binding to Notch receptor is dependent on DSL and the DOS
omains. Mammals have four Notch receptors, which all exhibit
he same overall structure: EGF-like repeats and an LNR domain
n the extracellular domain (NECD), several ankyrin-like repeats, a
EST domain, multiple nuclear localization sequences and a CSL-
inding site called RAM in the intracellular domain (NICD); as well
s a transmembrane domain (TM) (Bray, 2006; Bianchi et al., 2006).
n contrast to other DSL ligands, the inhibitory DLL3 did not activatey/Hematology 104 (2016) 21–29
Notch signaling pathway in multiple assays. Moreover, DLL3 did not
bind to cells expressing any of the four Notch receptors, and Notch1
did not bind DLL3-expressing cells (Ladi et al., 2005). Although new
insights into the Notch-ligand recognition event have been gained
from the application of structural biology, it is required to iden-
tify the afﬁnity of different Notch ligand complexes, including the
design of fragments for co-crystallization and ELISA based assays
of fragments of Notch and Delta (Chillakuri et al., 2012). The ligand
selectivity of Notch signaling and Notch-ligand therapeutics need
more investigation.
Once bound to its ligand on a neighboring cell, the Notch recep-
tor is activated, undergoing at least three critical proteolytic steps
(Kopan and Ilagan, 2009). In this vital process, ligand-receptor
binding triggers a metalloprotease cleavage of the Notch receptor
followed by proteolysis of the NICD by the -secretase complex.
Then, the NICD is free to attach itself to speciﬁc DNA-binding
proteins located in the nucleus, where it associates with the CSL
(CBF1/Su(H)/Lag-1) transcription factor complex, resulting in sub-
sequent activation of the canonical Notch target genes: myc, p21,
and the HES-family members (Efstratiadis et al., 2014).
3. The controversial roles of Notch signaling pathway in
breast cancer
The role of the Notch signaling pathway was recognized decades
ago when changes of Notch pathway members were found respon-
sible for various human diseases. Identiﬁcation of a recurrent
t(7;9)(q34;q34.3) chromosomal translocation was  discovered to be
related with the Notch1 gene, found in a small subset of human pre-
T-cell acute lymphoblastic leukemias (T-ALL) (Ellisen et al., 1991).
Since then, a list of aberrant Notch signaling has grown to include
cancer, immune disorders and developmental syndromes. Alag-
ille syndrome (an autosomal dominant genetic disorder) and the
late-onset syndrome CADASIL (cerebral autosomal dominant arte-
riopathy with subcortical infarcts and leukoencephalopathy) are
two classic epitomes of developmental diseases caused by muta-
tions of Notch2 and Notch3, respectively (Ortica et al., 2014; Joutel
et al., 1996). With similar but independent characters, Notch recep-
tors (Notch1, 3, 4) and ligands (JAG1 and DLL4) were all found to
be highly and widely expressed in human breast cancers, com-
pared with normal breast tissues from the margin of tumor section,
leading to abnormal growth of breast cancer cells (Zang et al., 2007).
The mechanism of cancer initiation and development is not
yet fully understood. One theory about the initiation and metas-
tasis of solid tumors, including breast cancer, is the involvement
of stem-like cells/cancer-initiating cells (CSC/CIC), whose par-
tial characteristics are known of increased CD44 and decreased
CD24 (CD44+/CD24−) (McCubrey et al., 2014; Al-Hajj et al., 2003).
Abundant studies on mutations in Notch signaling pathway have
presented its signiﬁcant roles in breast malignancies. For instance,
Notch1 inﬂuences breast CSC/CIC self-renewal by increasing HER2
transcription (Ju et al., 2013; Suman et al., 2013). Erythropoi-
etin (Epo) on the surface of breast CSC/CIC could increase the
CSC/CICs’ self-renewing capacity in a Notch-dependent manner
(Phillips et al., 2007). Harrison et al. (2010) evaluated the activa-
tion status of all Notch receptors in breast CSC/CIC as compared
to luminally differentiated CD24+ cells and found that the acti-
vation of Notch4 is much higher in BCSC-enriched cells while
Notch4 knock-down could suppress tumor initiation completely.
More precisely, Nagamatsu et al. (2014) pointed out that Notch4
over-expression increased the proliferation and invasiveness of
triple-negative breast cancer (TNBC) cells and Notch4 inhibition
reduced proliferation and invasiveness of TNBC cells as well as
tumor volume and tumorigenicity.
colog
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Moreover, numerous oncogenic pathways that crosstalk with
otch signaling has been described in Breast Cancer. The potential
eneﬁt of altering Notch signaling therapeutically, therefore, must
e balanced against the many biological roles played by the Notch
athway, including the roles of Notch pathway components that
ct as either oncogenes or tumor suppressors, depending on the
ype of crosstalk (Zhou et al., 2013).
Most lately, obesity, with its accompanying alterations in energy
etabolism, is recognized to be associated with increased risk of
umerous cancer types, including breast cancer (Battle et al., 2014;
arcia-Esquinas et al., 2015). In a non-randomized retrospective
tudy, a small number of breast cancer patients with type 2 dia-
etes mellitus (T2DM) were found more likely to be overweight
nd to have greater lymph nodes involvement. T2DM, in this case,
as statistically and clinically associated with poorer prognosis in
R/PR positive or HER2 negative breast cancer patients (He et al.,
015). Another interesting study demonstrated that Notch plays
n important role in regulation of energy metabolism. Inhibition of
otch promotes adipose browning and improved energy homeo-
tasis and suppressed weight gain in mice (Gridley and Kajimura,
014). Although there is yet no direct evidence in the case of breast
ancer, this new study represents an exciting ﬁrst step towards a
ole for Notch pathway inhibition as an effective therapeutic inter-
ention for obese patients with breast cancer.
. The degradative systems for Notch family members
Cellular function is tightly controlled by the balance of pro-
ein synthesis and degradation (Rothman, 2010). A considerable
mount of cellular energy is invested in regulating the rate of pro-
ein turnover. Almost all proteins in eukaryotic cells are constantly
eing degraded and replaced during the regulation of a series of
rocesses including cell-cycle division, DNA repair, cell growth
nd differentiation, and programmed cell death (Nakayama and
akayama, 2006). Precise regulation of Notch signaling is essen-
ial for normal function and requires both timely activation and
nactivation of NICDs (Barth and Kohler, 2014).
Lysosomal and ubiquitin-proteasomal degradation are two
ajor pathways involved in Notch turnover in eukaryotic cells
Goldberg, 2003). The lysosome, a vacuolar structure, is involved
n a non-selective cellular proteolytic pathway that contributes
argely to cell maintenance during the course of cell growth and
ging (Chondrogianni et al., 2002). However, the bulk of cellular
roteins (80%) are degraded after being tagged with ubiquitin. The
biquitin-proteasome system (UPS) is the major extra-lysosomal
achinery for protein degradation and is involved in the regula-
ion of cell growth, apoptosis, and gene expression. Degradation
f a protein via the UPS involves two discrete, independent, and
uccessive steps: (1) generation of a polyubiquitin chain cova-
ently conjugated to the protein substrate and (2) degradation of
he tagged protein by the 26S proteasome (Ciechanover et al.,
000a). Activated ubiquitin is successively transferred sequentially
o the protein of interest by activating enzyme (E1), conjugating
nzyme (E2), and ubiquitin ligase (E3); the ubiquitin molecules are
elivered to the epsilon-NH2 of the target protein lysine residues
Kulathu and Komander, 2012). Numerous E3s provide speciﬁcity
n that each ligase can modify only a subset of substrate proteins,
llowing the regulation of a diverse set of biological functions. Else-
here, the ubiquitin is recycled via a series of de-ubiquitin enzymes
DUBs) (Nakayama and Nakayama, 2006)..1. Ubiquitination-dependent degradation of Notch receptors
Notch is a relatively short-lived protein and undergoes rapid
egradation mainly through an ubiquitin-mediated pathway. Stud-y/Hematology 104 (2016) 21–29 23
ies of degradation of Notch family members have revealed that
each experience similar mechanisms of degradation based upon
homologous domains. The PEST domain, for example, is highly con-
served in all NICDs. A role for the PEST domain is likely to control
E3-mediated ubiquitin-dependent turnover of Notch (Ciechanover
et al., 2000b). One recent discovery indicated that this negative reg-
ulatory domain was  responsible for degrading active NICDs in TNBC
cells; yet, disruption of the PEST domain led to an increase in NICD
half-life (Wang et al., 2015). Pathways that regulate the stability of
NICDs as well as the protein complexes they form are still poorly
deﬁned (Fig. 1).
Early evidence of ubiquitination involvement in the Notch
signaling came from the identiﬁcation of the l(3)73Ai1 allele
in Drosophila melanogaster as a dominant temperature-sensitive
lethal mutation in a gene encoding a component of the proteasome
(Saville and Belote, 1993). Eric et al. summarized the preliminary
understanding of four E3s that regulate levels of the Notch receptor
and other components of this pathway, including Deltex/Itch, SEL-
10, Neuralized, and LNX (Lai, 2002; Hubbard et al., 1997). However,
Drosophila Notch contains a canonical PPxY motif that allows direct
binding of the receptor to the E3 ligase, which may not be similar
to mammalian Notch molecules. In this review, we will focus on
Notch ubiquitination and its interplay with cancer development,
especially in human breast cancer.
The importance of Notch1 in cancer development was  identi-
ﬁed in transgenic mousestrain containing mouse mammary tumor
virus (MMTV)/myc (Girard et al., 1996). Later, Notch1 was recog-
nized as a mediator of the Ras oncogene; mutations in Ras occur
in early breast cancer and act to promote carcinogenesis (Mittal
et al., 2014). A number of components and post-translational
modiﬁcations have been implicated in regulating Notch1 stabil-
ity in various cancer types, either positively or negatively (Brou,
2009). Previous studies in mammals have shown that an inacti-
vated Notch1 receptor is poly-ubiquitinated by the E3 ligases Fbw7
and Itch (Chastagner et al., 2008; Welcker and Clurman, 2008).
Puca et al. recently demonstrated that -arrestin was  required for
Itch-Notch1 interaction and, subsequently, for Itch-driven ubiq-
uitination and proteasomal degradation of Notch (Welcker and
Clurman, 2008). Similarly, the degradation of Notch1 mediated by
Itch was enhanced by a neuronal adaptor protein, Fe65, which is
capable of forming an Itch-Notch1 complex within the nucleus
(Kim et al., 2012). Salvatore et al. discovered that Numb, an adaptor
protein closely related to Notch degradation, possesses its speciﬁc
ubiquitinatioin and proteasomal degradation, so Notch signaling
is increased in Numb-negative breast tumors and reverts to basal
levels with enforced expression of Numb. On the other hand, knock-
down of Numb could up-regulate Notch signaling in Numb-positive
breast tumors (Pece et al., 2004). Evidence suggests that several
proteins are required for the regulated and ordered processes that
are necessary to recruit E3 ligase to Notch1.
In some cases, poly-ubiquitinated substrates could be resistant
to proteasome degradation. Recent studies have provided a deeper
understanding of non-degradative ubiquitination of Notch1. For
example, MDM2,  an E3 for p53 ubiquitination, plays an important
role in regulating the Notch signaling pathway through its inter-
action with Notch regulator, NUMB (Pei et al., 2012). Although the
binding interaction between Notch1 and MDM2 results in Notch1
ubiquitination, degradation of Notch1 does not occur, leading to
activation of N1ICD (Sczaniecka et al., 2012). Moreover, MDM2
can synergize with Notch1 to inhibit apoptosis and promote pro-
liferation. This highlights yet another target for MDM2-mediated
ubiquitination that results in activation of the protein rather than
degradation and makes MDM2  an attractive potential target for
drug discovery via both the p53 and Notch signaling pathways
(Pettersson et al., 2013).
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dig. 1. Schematic diagram of the Notch signaling pathway. Membrane-tethered No
inding  to their appropriate ligands (Delta/Delta-like or Serrate/Jagged), an initial c
n  the release of the intracellular domain of Notch (NICD). NCID then translocates t
ignals. The E3 ligases, Itch and Fbw7/Sel-10, ubiquitinate the Notch receptor and N
The function of human Notch2, the receptor with greatest
omology to Notch1, has only been studied in a very limited
ay. O’Neill et al. found that expression of the N2ICD may  cause
ncreased apoptosis in MDA-MB-231 breast cancer cells in vitro
O’Neill et al., 2007). Inactivation of Notch2 in a B-cell chronic lym-
hocytic leukemia (B-CLL) cell line resulted in down-regulation
f CD23, therefore, loss of Notch2 activities may  occur during
he early steps of apoptosis. Proteasome-regulated degradation of
otch2 was conﬁrmed using proteasome inhibitor-induced apop-
otic response in B-CLL lymphocytes (Duechler et al., 2005).
Notch3 was shown to play a critical role in cancer development
s evidenced by Notch3 ampliﬁcation and rearrangement observed
n several human cancers (Allenspach et al., 2002). In a previous
tudy, we have proved that active Notch3 could up-regulate Cdh1
nd cause p27Kip accumulation ultimately, leading to cell cycle
rrest at the G0/G1 phase, suggesting its role as tumor suppressor
Chen et al., 2015). In terms of protein stability, Notch3 is mainly
egraded by the lysosomal system in most cancers cases, which dif-
erentiates it from Notch1 and Notch4 (Zhang et al., 2007). Wang
t al. found the lysosomal inhibitors Chloroquine and NH4Cl could
ead to greater accumulation of transfected and endogenous N3ICD
n various cell lines including HeLa cells (Jia et al., 2009). Interest-
ngly, when screening for N3ICD interacting proteins using a human
roteome microarray, Jung et al. (2014) identiﬁed the E3 ligase,
WP2, as a top candidate for interaction with Notch3. Their results
lso showed that, in ovarian cancers, N3ICD was the only Notch
omologue that interacted with WWP2. Wild-type WWP2, but not
igase-deﬁcient mutant WWP2, increased mono-ubiquitination of
he membrane tethered Notch3 fragment, thus attenuating Notch3
athway activity in cancer cells and leading to cell cycle arrest.
n T-cell leukemia, N3ICD was regulated by ubiquitin-proteasome
egradation and further identiﬁed N3ICD as an acetylatable pro-ceptors are synthesized as precursor proteins and cleaved during transport. After
e event is triggered by metalloprotease followed by -secretase cleavage, resulting
nucleus, causing transactivation of target genes. Numb negatively regulates Notch
espectively, thereby promote their degradation. See the text for additional details.
tein. Acetylation of N3ICD occurs at K1692 and K1731, leading to
N3ICD proteasomal degradation and down-regulation of N3ICD-
triggered signaling (Palermo et al., 2012). Very limited data has
been published regarding the role of Notch3 in breast cancer.
Independent studies have demonstrated an important role for
UPS on Notch4 degradation. As previously described, Sel-10 regu-
lates the activities of Notch receptors through targeting NICD for
UPS-mediated degradation (Wang et al., 2014). However, the fates
of ubiquitinated N1ICD and N4ICD in vitro are different. Sel-10
interacts with both N1ICD and N4ICD. In addition, blocking endoge-
nous Sel-10 stabilizes N1ICD while there was  no observed impact
on N4ICD stability (Wu  et al., 2001). Ubiquitination of the ICD
requires the presence of the most carboxyl-terminal region, includ-
ing the PEST domain, moreover, ubiquitination usually results
in the reduction of N1ICD-mediated activation of the HES1 pro-
moter. This degradation and negative regulation trend was  partially
reversed by proteasome inhibitor, MG132 (Oberg et al., 2001). As
mentioned before, MDM2  can also activate N1ICD through ubiq-
uitination, however, this process may  be suppressed by Trp53 via
a trimeric complex composed of Trp53, Notch4 and Mdm2, which
ultimately regulates Notch activity in Notch4-associated tumori-
genesis in the mammary gland (Sun et al., 2011). The mechanism
by which Notch4 regulates CSC/CIC activity is not fully understood,
but interaction with the peptidyl-prolyl-isomerase, Pin1, leads to
an escape from proteasomal degradation in human breast cancer
cells (Rustighi et al., 2014).
4.2. Regulation of Notch ligands activity by ubiquitinationIn addition to controlling receptor activities, recent studies have
revealed the key role that ubiquitination of various components has
played among Notch ligands. In Drosophila, two canonical RING-
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ontaining E3 ligases, Neuralized (Neur) and Mind bomb (Mib),
nﬂuence Notch signaling through the ubiquitination of Notch lig-
nds, Delta, to stimulate their internalization (Daskalaki et al.,
011). But molecular roles of these E3s may  be distinct between
ertebrates and insects. For instance, Koo et al. suggested that
ib1 is essential for Jagged as well as Delta-like ligand-mediated
otch signaling in mammals, in contrast with Neur1, Neur2 and
ib2, which are dispensable for Notch signaling (Koo et al., 2007;
oretti and Brou, 2013). Le Bras et al. provided an overview to
iscuss ligands selectivity and subsequent signal diversiﬁcation
mong Notch1-4. Furthermore, subtype speciﬁc-regulation by E3s
nd DUBs were involved in the regulation of both Notch receptors
nd DSL (Delta/Serrate/LAG-2) ligands (Le Bras et al., 2011).
Apart from the requirement of E3 ubiquitin ligases activities,
wo phenomena requiring ubiquitination and necessary for Notch
ignaling activity of ligands have been described: (1) transendocy-
osis, allowing the recruitment of ligand endocytosis and thereafter
eceptor proteolysis (Kandachar and Roegiers, 2012), and (2) recy-
ling of the ligands, which requires DLL1 in most mammal  cases
Previs et al., 2015). cis-Inhibition is another unique phenomenon
nvolving Notch receptor and ligands, independent of ubiquitina-
ion of the ligands (del Alamo et al., 2011). To put together, these
esults highlight the importance of ubiquitination events taken by
otch ligands. However, a more complete understanding of the
echanism by which ligand ubiquitination is related to disease
rogression and cancer formation is needed.
.3. Inhibition of the Notch signaling pathway rather than
rotein degradation
Recently, researchers have identiﬁed speciﬁc targets, which can
nhibit Notch activity and its signaling pathway and thus prevent
ancer development and progression. Here we  review some lat-
st strategies for Notch inhibition used in breast cancer therapies,
orted by distinct binding sites being targeted.
.4. Cleavage to NICD
Several potential strategies for Notch inhibition have focused on
he initial interaction and cleavage process. Ligand-induced ADAM-
ype metalloprotease cleavage of Notch transmembrane receptors
t the extracellular negative regulation region (NRR) is essential for
ater secretase processes and is required to activate the Notch sig-
aling pathway (Brou et al., 2000). This blocking pathway has been
xtensively studied and shown to have roles in various molecular
ypes of breast cancers. However, most of the studies in breast can-
er were focused on chemo- or endocrine therapies and did not
ddress the clinical signiﬁcance of Notch suppression (McGowan
t al., 2013; Feldinger et al., 2014).
Other investigators generated a series of Notch decoys to imi-
ate receptor-ligand modiﬁcation in order to inhibit Notch, mimic
he ligand-binding region of Notch transmembrane receptors, and
revent their interaction with ligands by competitive inhibition
Kangsamaksin et al., 2015). By using a soluble receptor Notch1
ecoy, Banerjee et al. (2015) showed that inhibition of Notch unex-
ectedly caused a remarkable increase in liver metastases from
euroblastoma and breast cancer cells and inhibition of DLL1/4
ith ligand-speciﬁc Notch1 decoys increased sprouting of sinu-
oidal endothelial cells into micro-metastases and supported early
etastatic angiogenic growth. Though promising, the levels of
ecoy required to consistently impede Notch signaling have not
et been determined.Activation of Notch receptors is highly dependent upon a
-secretase complex, thus inhibition of -secretase by small
olecules offers a promising approach and has already been exten-
ively used to study the downstream targets of the Notch signalingy/Hematology 104 (2016) 21–29 25
pathway in the laboratory (Olsauskas-Kuprys et al., 2013). It is
reported that -secretase inhibitors (GSIs) target any Notch recep-
tors (Wang et al., 2015). Surprisingly, inactivation of Notch3 by
-secretase inhibitors decreased cellular proliferation and induced
apoptosis in ovarian cancer cell lines, suggesting that Notch3
expression may  be related to chemoresistance and that the Notch3
pathway may represent as a novel potential therapeutic target
for advanced stage chemoresistant ovarian cancer (Rahman et al.,
2012). These compounds have showed promising results in can-
cer, despite their off-target effects. It is important to note that
-secretase targets four Notch receptors, but also cleaves other tar-
gets, such as Notch ligands Delta-like and Jagged, CD44, Nectin-1
alpha, E-cadherin and so on (Ikeuchi and Sisodia, 2003; Kim et al.,
2002; Lammich et al., 2002; Marambaud et al., 2002). Thus, the GSIs,
the only known Notch inhibitors in clinical trials currently, lack the
speciﬁcity to each Notch family member.
4.5. Biological regulation within nucleus
The ﬁnal cleavage carried out by a -secretase complex leads to
the release of NICD (Brou, 2009). NICD translocates to the nucleus
and functions as a transcription factor, interacting with binding
protein Suppressor of Hairless (RBPJ), and the transcriptional acti-
vator protein Mastermind, to regulate target gene such as Hes-1
and Hey-1 (Yan et al., 2002; Katoh and Katoh, 2007). As mentioned
above, Numb can disturb this transcriptional machinery and inhibit
Notch-dependent gene expression, therefore an inverse relation-
ship between Numb and Notch can be observed (Flores et al., 2014).
Notch has been shown to be involved in cell–cell commu-
nication via numerous endogenous miRNAs (Fan et al., 2013).
For instance, miR-34a is down-regulated in human breast cancer
(Peurala et al., 2011). Le et al. further veriﬁed that miR-34a inhibited
breast cancer stemness and increased chemosensitivity to pacli-
taxel, partially by down-regulating the Notch1 pathway, suggesting
that miR-34a/Notch1 play an important role in regulating breast
CSC/CIC (Kang et al., 2015). Consistent with this model, miR-34c
down-regulation via DNA methylation has been shown to correlate
with self-renewal and epithelial-mesenchymal transition (EMT) in
breast tumor-initiating cells as well as to suppress migration via
silencing the target gene Notch4 (Yu et al., 2012).
4.6. Alteration of NICD post-translational modiﬁcations
Besides ubiquitination, other post-translational modiﬁcations
of NICD serve to enable inactivation of NICD and need to be further
examined in the setting of breast cancer. Targeting these modiﬁ-
cations could provide additional promising targets for therapeutic
intervention.
Phosphorylation of Notch proteins has been indirectly corre-
lated with Notch activation and nuclear translocation as well as
cellular transformation. Phosphorylation can either activate or
deactivate NICD, depending on the number of cleavages the Notch
transmembrane protein experiences and the speciﬁc kinase pro-
tein involved (Flores et al., 2014). The Notch signaling pathway
is regulated by glycogen synthase kinase 3 (GSK-3). GSK-3 phos-
phorylation can decrease Notch1 protein levels and reduce Notch
transcriptional activity (Jin et al., 2009). This data suggests that
GSK-3 beta-dependent phosphorylation can speciﬁcally regulate
activation of the Notch molecule (Espinosa et al., 2003).
In response to hypoxic conditions, hydroxylation of Notch1 sig-
naling occurs at the N1ICD N1945 and N2012 residues when HIF-1
is induced, thereby leading to severe impairment of N1ICD in HeLa
cells (Coleman et al., 2007). As yet, there are only limited reports of
Notch hydroxylation in breast cancer.
Glycosylation of Notch proteins occurs during transit through
the endoplasmic reticulum (ER) and Golgi apparatus where the
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lycosylation machinery (glycosyltransferases) work just like an
ssembly line, adding glycans in a progressive manner. Glycosyla-
ion of the Notch extracellular domain has emerged as an elegant
eans for regulating Notch activity (Takeuchi and Haltiwanger,
014). Fringe proteins are able to positively and negatively reg-
late Notch ligands, but their diverse roles in breast cancer are still
nclear (Moloney et al., 2000). It was reported that the majority of
embrane glycoproteins, including Notch, with bisecting glycosy-
ation are common to both serous and endometrioid histological
ubtypes of ovarian cancer (Allam et al., 2015).
Recently, Hein et al. (2015) reported another post-translational
odiﬁcation of N1ICD, a site-speciﬁc methylation of N1ICD. They
bserved that methylation of N1ICD occurred at ﬁve arginine
esidues within the C-terminal trans-activation domain and the
1ICD was biochemically less stable than a methylation-defective
1ICD mutant, predicting that methylation of N1ICD may  be the
ssential modiﬁcation for Notch signaling pathway.
. Clinical implications
Current breast cancer therapy is based on its histology, molec-
lar sub-types and TNM stages, traditionally consists of multi-
isciplinary regimens, including surgical-, chemo-, hormone-,
adio-, therapy. However, side effects are constant problems in
any trials for new cytotoxic therapies but for targeted therapies
s well. Ongoing progress in this ﬁeld is critical for the development
f new cancer therapies and for the improvement of those already
n use (Chen et al., 2014). The clinical potential Notch signaling
athway inhibition is of increasing clinical interests.
.1. Current therapeutic Notch-signaling-targeting agents
Modulating Notch pathway at any point from receptor mat-
ration to receptor-ligand interaction, NICD release or cofactor
ecruitment would affect its signaling output. Current therapeu-
ic interventions focus on inhibiting receptor-ligand interactions
nd interfering with the proteolytic processing of the receptors
Groth and Fortini, 2012). The -secretase complex is responsi-
le for releasing the NICD, and GSIs, such as DAPT, are used to
lock this cleavage, abrogating canonical Notch signaling in the
ell. Serial GSIs are under development in preclinical studies and
linical trials (Golde et al., 1828), most of which are potential
herapeutics for Alzheimer’s disease (Olson and Albright, 2008).
mong them, MK-0752 was used in patients with advanced solid
umors. Interestingly, preclinical data showed that pharmacologic
nhibition of the Notch pathway can reduce breast CSC/CIC popu-
ations in tumor-xenograft models. Thus there is the potential to
se Notch pathway inhibitors in combination with chemotherapy
n breast cancer (Schott et al., 2013). PF-03084014, another GSI,
e-sensitizes breast cancer cells to docetaxel in preclinical mod-
ls (Zhang et al., 2013), and has also been used in patients with
dvanced solid malignancies to estimate the maximum tolerated
ose for continuous oral administration. A phase I study showed
hat PF-03084014 was generally safe and well tolerated, and dis-
layed a dose-dependent pharmacokinetic proﬁle in patients with
dvanced solid tumors. What more, the further development of
F-03084014 for the treatment of patients with advanced solid
umors is ongoing in advanced TNBC and metastatic pancreatic
ancer (Messersmith et al., 2015). However, GSIs fail to distin-
uish between individual Notch receptors, inhibit other signaling
athways, and probably contribute to dual or pan-Notch inhibition
mong Notch1 and other family members (Guo et al., 2011).
Given the GSIs’ non-speciﬁcity, antibodies against Notch, block-
ng protein–protein interactions or part of a protein structure, are a
otential approach for disrupting Notch signaling, allowing for tar-y/Hematology 104 (2016) 21–29
geting of individual Notch family members or ligands speciﬁcally.
The Notch1 anti-NRR (the negative regulatory region) had anti-
tumor potential without gut toxicity associated with combined
Notch1 and Notch2 inhibition. However, the delivery for the large
molecules is a big obstacle to process new antibodies as anti-cancer
drugs (Wu et al., 2010).
5.2. Natural compounds
Several natural compounds have been investigated for their
ability to inhibit Notch signaling, but their mechanisms have not
yet been determined. Genistein, an isoﬂavonoid in soy, has been
demonstrated to be a protective factor against breast cancer as
it can inhibit the growth of MDA-MB-231 triple-negative breast
cancer cells by inhibiting NF-B activity via the Notch-1 signaling
pathway (Pan et al., 2012). Kumar et al. (2002) supplied genis-
tein to premenopausal, omnivorous women  to evaluate the role of
isoﬂavones in producing a change in steroid hormones and men-
strual cycle length. Additionally, the authors found that increased
genistein intake affects estrogen metabolism by decreasing the
steroid hormone concentration, and demonstrates the potential to
reduce the risk of breast cancer (Kumar et al., 2002). Recently, a
randomized placebo-controlled study focused on the effect of soy
supplementation on breast cancer-related genes and found that
gene expression associated with soy intake and high plasma genis-
tein is characterized by over-expression of FGFR2 and genes that
drive cell cycle and proliferation pathways. Therefore, these ﬁnd-
ings indicated that soy may  exert a stimulating effect on breast
cancer in a subset of women (Shike et al., 2014). Sulporaphane, a
product found in broccoli, can inhibit Notch signaling by induc-
ing the G2/M arrest via increased expression of cyclin B1 and was
also able to induce oligonucleosomal DNA fragmentation in human
breast cancer cell lines (Pledgie-Tracy et al., 2007; Licznerska et al.,
2015). Other compounds, for instance, resveratrol and curcumin,
have all been shown to result in downregulation of the Notch1
signaling pathway in breast cancer (Li et al., 2011). However, the
mechanism by which natural compounds regulate the Notch path-
way in breast cancer is complex and unclear, further preclinical and
clinical studies are needed to investigate the potential beneﬁts of
these natural compounds in patients with breast cancer.
5.3. Targeting the Notch ubiquitination pathway for cancer
therapy
Several clinical trials targeting the UPS have been carried out
worldwide. Knowledge of how to alter ubiquitination is beginning
to be exploited for both molecular diagnostics and the develop-
ment of novel strategies to combat cancer (Hoeller and Dikic, 2009).
Bortezomib, a proteasome inhibitor, was  approved by U.S. Food and
Drug Administration for the treatment of patients with multiple
solid cancers (Sterz et al., 2008). Thaler et al. (2015) demonstrated
that bortezomib inhibited expression of multiple genes associ-
ated with poor prognosis in ER positive breast cancer patients
by increasing expression of cyclin-dependent kinase inhibitors.
However, several clinical studies reported contrasting results for
patients with advanced/metastatic breast cancer (Trinh et al., 2012;
Schmid et al., 2008; Engel et al., 2007). Further studies are needed to
explore the response of patients with breast cancer to bortezomib
and to uncover the mechanisms by which bortezomib effects Notch
signaling and function.
Regarded as a response to oncogenic signals, E3 ligases are of
interest as drug targets for their ability to regulate protein sta-
bility and function (Bond et al., 2005). Novel approaches include
identifying smaller molecules that can bind to the substrates and
potentially prevent the actions of multiple ligases (Micel et al.,
2013). Fbw7, an E3 ligase with well-known substrates including
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yclin E, Myc, Jun, and Notch, plays a central role in cell division,
rowth, and differentiation. Clappier et al. (2010) investigated the
rognostic implication of mutations in Notch and/or Fbw7 in chil-
ren with T-ALL enrolled in EORTC-CLG trials and found that the
ncidence of isolated central nervous system relapse was  relatively
igh in Notch1 positive patients, although it is still unclear whether
he FBW7 mutation is related to a higher propensity of a tumor to
e Notch positive.
Although E3 provides speciﬁcity to substrates in the last stage
efore ubiquitination, the activating enzyme, E1, is also impor-
ant in the process of UPS. Several studies are set to investigate
iverse E1 inhibitors for their ability to regulate the Notch sig-
aling pathway. In a preclinical model, pevonedistat (MLN4924),
 NEDD8-activating enzyme inhibitor, could function as a radio-
ensitizing agent in breast cancer cell in vivo (Yang et al., 2012).
n a phase I study, pevonedistat was used in patients with acute
yeloid leukemia (AML) and myelodysplastic syndromes (MDS)
o determine the dose-limiting toxicities and maximum tolerated
ose and reported that administration of pevonedistat was feasi-
le in these patients (Swords et al., 2015). The application of E1
nhibitor to the treatment of other tumor types may  be beneﬁcial
o additional patients.
. Concluding remarks
The identiﬁcation of Notch degradation is invaluable to the
iscovery of potential therapeutic targets in breast cancer. New
nsights describing the crosstalk among protein degradation
athways may  provide new therapeutic modalities for cancer treat-
ent. Understanding more about protein degradation could serve
s another tool for biomedical researchers and physicians to dis-
over novel and promising treatments for malignant diseases. A
arge body of evidence, coming mostly from in vitro cell culture,
as provided molecular explanations of how alterations in Notch
egradation can contribute to the etiology and development of
ifferent types of tumors, including breast cancer. As Notch has
volutionarily conserved roles in cell-fate determination and tumor
rogression, its biological pathways are currently being examined
s potential targets for anti-cancer therapies. It might be possible to
electively target the involvement of Notch in breast cancer and to
dentify patients most likely to beneﬁt from Notch inhibition. The
ole of Notch degradation in breast cancer should be examined as
n issue of utmost importance.
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